Legend: : Special Mention : Important ![]() : Very Important ![]() ![]() : Key Development |
||
![]() ![]() |
Lack of intestinal mucosal toxicity of Triticum monococcum in celiac disease patients. D Pizzuti, A Buda, A D'Odorico, R D'Incà, S Chiarelli, A Curioni, D Martines, Scand J Gastroenterol. 2006 Nov:1305-11 |
|
![]() |
Screening of the adult population in Iran for coeliac disease: comparison of the tissue-transglutaminase antibody and anti-endomysial antibody tests. MR Akbari, A Mohammadkhani, H Fakheri, M Javad Zahedi, B Shahbazkhani, M Nouraie, M Sotoudeh, R Shakeri, R Malekzadeh, Eur J Gastroenterol Hepatol. 2006 Nov:1181-6 |
|
![]() |
The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. BM Paterson, KM Lammers, MC Arrieta, A Fasano, JB Meddings, Aliment Pharmacol Ther. 2007 Sep 1:757-66 |
|
| ATG16L1 and IL23R Are Associated With Inflammatory Bowel Diseases but Not With Celiac Disease in The Netherlands. RK Weersma, A Zhernakova, IM Nolte, C Lefebvre, JD Rioux, F Mulder, HM van Dullemen, JH Kleibeuker, C Wijmenga, G Dijkstra, Am J Gastroenterol. 2008 Mar:621-7 |
||
| European multi-centre study on coeliac disease and non-Hodgkin lymphoma. ML Mearin, C Catassi, N Brousse, R Brand, P Collin, E Fabiani, JJ Schweizer, M Abuzakouk, H Szajewska, C Hallert, C Farré Masip, GK Holmes, Biomed Study Group on Coeliac Disease and Non-Hodgkin Lymphoma, Eur J Gastroenterol Hepatol. 2006 Feb:187-94 |
||
| Oats in the treatment of childhood coeliac disease: a 2-year controlled trial and a long-term clinical follow-up study. K Holm, M Mæki, N Vuolteenaho, K Mustalahti, M Ashorn, T Ruuska, K Kaukinen, Aliment Pharmacol Ther. 2006 May 15:1463-72 |
||
| Urinary nitric oxide during one year of gluten-free diet with or without oats in children with coeliac disease. E Hollén, T Forslund, L H&oeig;gberg, P Laurin, L Stenhammar, K Fælth-Magnusson, KE Magnusson, T Sundqvist, Scand J Gastroenterol. 2006 Nov:1272-8 |
||
| Usefulness of the organ culture system in the in vitro diagnosis of coeliac disease: a multicentre study. A Picarelli, M Di Tola, L Sabbatella, MC Anania, A Calabrò, D Renzi, JC Bai, E Sugai, A Carroccio, L Di Prima, MT Bardella, D Barisani, C Ribes-Koninckx, ED Aliaga, M Gasparin, E Bravi, Multicentre Organ Culture System Study Group, Scand J Gastroenterol. 2006 Feb:186-90 |
||
| Supplementary evidence: | ||
| Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease. E Bolognesi, K Karell, S Percopo, I Coto, L Greco, V Mantovani, E Suoraniemi, J Partanen, K Mustalahti, M Mæki, P Momigliano-Richiardi, Tissue Antigens. 2003 Apr:308-16 |
||
| Antiendomysium versus antigliadin antibodies in screening the general population for coeliac disease. C Catassi, G Fanciulli, AR D'Appello, R El Asmar, C Rondina, E Fabiani, I Bearzi, GV Coppa, Scand J Gastroenterol. 2000 Jul:732-6 |
||
| Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men. D Bai, P Brar, S Holleran, R Ramakrishnan, PH Green, Scand J Gastroenterol. 2005 Feb:183-7 |
||
| Evidence for increased apoptosis of duodenal intraepithelial lymphocytes in cow's milk sensitive enteropathy. MT Augustin, J Kokkonen, TJ Karttunen, J Pediatr Gastroenterol Nutr. 2005 Mar:352-8 |
||
| The molecular basis for oat intolerance in patients with celiac disease. H Arentz-Hansen, B Fleckenstein, Ø Molberg, H Scott, F Koning, G Jung, P Roepstorff, KE Lundin, LM Sollid, PLoS Med. 2004 Oct:e1 |
||